Novartis has acquired DTx Pharma, a US-based, preclinical-stage biotechnology company, for an upfront payment of $500 million plus additional payments of up to $500 million, dependent on the completion of pre-specified milestones, the companies announced in their respective July 17, 2023 press releases.
DTx Pharma focuses on RNA-based therapeutics with its proprietary Fatty Acid Ligand Conjugated OligoNucleotide (FALCON) technology platform, which conjugates small interfering RNAs (siRNAs) to naturally occurring fatty acids to enhance biodistribution and cellular uptake throughout the body.
